IP Verse

Formulation For Anti- 4 7 Antibody - EP2704742

The patent EP2704742 was granted to Millennium Pharmaceuticals on Jul 12, 2017. The application was originally filed on May 2, 2012 under application number EP12722973A. The patent is currently recorded with a legal status of "Revoked".

EP2704742

MILLENNIUM PHARMACEUTICALS
Application Number
EP12722973A
Filing Date
May 2, 2012
Status
Revoked
Dec 19, 2022
Grant Date
Jul 12, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

DEHMEL & BETTENHAUSENApr 12, 2018RUCKERLADMISSIBLE
GILL JENNINGS & EVERYApr 12, 2018GILL JENNINGS & EVERYADMISSIBLE

Patent Citations (31) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0404097
DESCRIPTIONGB2209757
DESCRIPTIONUS2004033561
DESCRIPTIONUS2005095238
DESCRIPTIONUS2007122404
DESCRIPTIONUS2010254975
DESCRIPTIONUS4816567
DESCRIPTIONUS5122464
DESCRIPTIONUS5500362
DESCRIPTIONUS5821337
DESCRIPTIONUS5827739
DESCRIPTIONUS5840299
DESCRIPTIONUS7147851
DESCRIPTIONUS7528236
DESCRIPTIONWO03099773
DESCRIPTIONWO2004046092
DESCRIPTIONWO2007061679
DESCRIPTIONWO2008140602
DESCRIPTIONWO8907142
DESCRIPTIONWO9311161
DESCRIPTIONWO9429351
DESCRIPTIONWO9624673
DESCRIPTIONWO9806248
INTERNATIONAL-SEARCH-REPORTUS2005095238
INTERNATIONAL-SEARCH-REPORTWO2008071394
INTERNATIONAL-SEARCH-REPORTWO2009009407
OPPOSITIONWO2007007159
OPPOSITIONWO2007061679
OPPOSITIONWO2007092772
OPPOSITIONWO2012151248
OPPOSITIONWO9806248

Non-Patent Literature (NPL) Citations (9) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Anonymous, "Tween 80 Product Information Product no P 8074", Sigma-Aldrich, (20060501), XP055484673
OPPOSITION- JANEWAY et al., "The structure of a typical antibody molecule", JANEWAY et al., JANEWAY et al., Immunobiology: The Immune System in Health and Disease, New York, Garland Publishing, (20010000), page 95, XP055484660
OPPOSITION- Krishnan et al., "Development of formulations for therapeutic monoclonal antibodies and Fc fusion proteins", Krishnan et al., Jameel et al., Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals, Hoboken, USA, John Wiley & Sons, pages 383 - 427, 469-472, 692- 694, XP055484494
OPPOSITION- "Sigma Product Information Sheet Tween 20 (P 5927)", Sigma-Aldrich, (20030000), XP055063445
OPPOSITION- "Vedolizumab", Drugbank, (20150215), Database accession no. DB09033, XP055484486
OPPOSITION- WANG et al., "ANTIBODY STRUCTURE, INSTABILITY, AND FORMULATION", J Pharm Sci., (20070100), vol. 96, no. 1, pages 1 - 26, XP009084505
OPPOSITION- GOKARN et al., "Self-buffering antibody formulations", J. Pharm. Sci., (20080000), vol. 97, no. 8, pages 3051 - 3066, XP002638374
OPPOSITION- MAHLER et al., "Protein aggregation: Pathways, induction factors and analysis", Pharm Sci., (20090900), vol. 98, no. 9, pages 2909 - 2934, XP055321457
OPPOSITION- ARAKAWA et al., "Biotechnology applications of amino acids in protein purification and formulations", Amino Acids, (20070316), vol. 33, no. 4, pages 587 - 605, XP019565540

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents